Sandoz Receives EC Approval of Ondibta (Biosimilar, Lantus and SoloStar)

Shots: The EC has approved Ondibta, a biosimilar insulin glargine pre-filled pen, reference medicine Lantus and SoloStar, developed and registered by Gan & Lee Pharmaceuticals, anticipated launch by early 2027 Ondibta is approved for treating diabetes mellitus in pts (age≥ 2 yrs.) and matches Lantus, SoloStar in safety, quality, and efficacy In Dec 2018, Sandoz partnered with…

ByDipanshu DixitJanuary 15, 2026

Navigating SLE Care with Saphnelo SC: A Conversation with Pablo Panella from AstraZeneca

Shots: Did you know that patients living with SLE in the EU face a two- to threefold higher risk of mortality compared to the general population? This stark reality underscores the need for therapies that are not only effective but also easier to administer AstraZeneca’s Saphnelo has recently been recommended for approval in the EU as a…

BySaurabh ChaubeyNovember 17, 2025

Top Performing Drug – Dupixent (April Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc. PharmaShots…

BySenior EditorApril 26, 2023

Sandoz Receives EC Approval of Ondibta (Biosimilar, Lantus and SoloStar)

Navigating SLE Care with Saphnelo SC: A Conversation with Pablo Panella from AstraZeneca

Top Performing Drug – Dupixent (April Edition)

Contact US

FOLLOW US